A personalized intervention to prevent depression in primary care: cost-effectiveness study nested into a clustered randomized trial

Anna Fernández, Juan M Mendive, Sonia Conejo-Cerón, Patricia Moreno-Peral, Michael King, Irwin Nazareth, Carlos Martín-Pérez, Carmen Fernández-Alonso, Antonina Rodríguez-Bayón, Jose Maria Aiarzaguena, Carmen Montón-Franco, Antoni Serrano-Blanco, Inmaculada Ibañez-Casas, Emiliano Rodríguez-Sánchez, Luis Salvador-Carulla, Paola Bully Garay, María Isabel Ballesta-Rodríguez, Pilar LaFuente, María Del Mar Muñoz-García, Pilar Mínguez-Gonzalo, Luz Araujo, Diego Palao, María Cruz Gómez, Fernando Zubiaga, Desirée Navas-Campaña, Jose Manuel Aranda-Regules, Alberto Rodriguez-Morejón, Juan de Dios Luna, Juan Ángel Bellón, Anna Fernández, Juan M Mendive, Sonia Conejo-Cerón, Patricia Moreno-Peral, Michael King, Irwin Nazareth, Carlos Martín-Pérez, Carmen Fernández-Alonso, Antonina Rodríguez-Bayón, Jose Maria Aiarzaguena, Carmen Montón-Franco, Antoni Serrano-Blanco, Inmaculada Ibañez-Casas, Emiliano Rodríguez-Sánchez, Luis Salvador-Carulla, Paola Bully Garay, María Isabel Ballesta-Rodríguez, Pilar LaFuente, María Del Mar Muñoz-García, Pilar Mínguez-Gonzalo, Luz Araujo, Diego Palao, María Cruz Gómez, Fernando Zubiaga, Desirée Navas-Campaña, Jose Manuel Aranda-Regules, Alberto Rodriguez-Morejón, Juan de Dios Luna, Juan Ángel Bellón

Abstract

Background: Depression is viewed as a major and increasing public health issue, as it causes high distress in the people experiencing it and considerable financial costs to society. Efforts are being made to reduce this burden by preventing depression. A critical component of this strategy is the ability to assess the individual level and profile of risk for the development of major depression. This paper presents the cost-effectiveness of a personalized intervention based on the risk of developing depression carried out in primary care, compared with usual care.

Methods: Cost-effectiveness analyses are nested within a multicentre, clustered, randomized controlled trial of a personalized intervention to prevent depression. The study was carried out in 70 primary care centres from seven cities in Spain. Two general practitioners (GPs) were randomly sampled from those prepared to participate in each centre (i.e. 140 GPs), and 3326 participants consented and were eligible to participate. The intervention included the GP communicating to the patient his/her individual risk for depression and personal risk factors and the construction by both GPs and patients of a psychosocial programme tailored to prevent depression. In addition, GPs carried out measures to activate and empower the patients, who also received a leaflet about preventing depression. GPs were trained in a 10- to 15-h workshop. Costs were measured from a societal and National Health care perspective. Qualityadjustedlife years were assessed using the EuroQOL five dimensions questionnaire. The time horizon was 18 months.

Results: With a willingness-to-pay threshold of €10,000 (£8568) the probability of cost-effectiveness oscillated from 83% (societal perspective) to 89% (health perspective). If the threshold was increased to €30,000 (£25,704), the probability of being considered cost-effective was 94% (societal perspective) and 96%, respectively (health perspective). The sensitivity analysis confirmed these results.

Conclusions: Compared with usual care, an intervention based on personal predictors of risk of depression implemented by GPs is a cost-effective strategy to prevent depression. This type of personalized intervention in primary care should be further developed and evaluated.

Trial registration: ClinicalTrials.gov, NCT01151982. Registered on June 29, 2010.

Keywords: Cost-effectiveness; Depression; Risk assessment.

Conflict of interest statement

Ethics approval and consent to participate

The PredictD-CCRT study has been approved by the relevant ethics committees in each participating Spanish city: Ethics Committee on Human Research of the University of Granada, Ethics and Research Committee of Primary Health District of Malaga, Ethics Committee for Clinical Research of Sant Joan de Deu Foundation (Barcelona) (PIC CEIC-62-09), Ethics Committee for Clinical Research of Aragon (CEICA) (CP06/05/2009), Ethics Committee for Health Research of the Jaen Hospital, Ethics Committee for Clinical Research of Euskadi (CEIC-E) (03/2009) and Ethics Committee for Clinical Research of the Rio Hortega Hospital of Valladolid (04/2009).

Consent for publication

Not applicable.

Competing interests

This work was only supported by public grants. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. No conflict of interests was reported by the authors of this paper. Dr. Antoni Serrano-Blanco reports grants from Ferrer International outside the submitted work, but none of the other authors have financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years.There are no other relationships or activities that could appear to have influenced the submitted work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Cost-effectiveness planes
Fig. 2
Fig. 2
Cost-effectiveness acceptability curves (CEACs): societal perspective
Fig. 3
Fig. 3
Cost-effectiveness acceptability curves (CEACs): National Health System perspective

References

    1. Global Burden of Disease Study C Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800. doi: 10.1016/S0140-6736(15)60692-4.
    1. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, et al. Cost of disorders of the brain in Europe 2010. EurNeuropsychopharmacol. 2011;21(10):718–79. doi: 10.1016/j.euroneuro.2011.08.008.
    1. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, Whiteford HA. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013;43(3):471–81. doi: 10.1017/S0033291712001511.
    1. Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry. 2004;184:526–33. doi: 10.1192/bjp.184.6.526.
    1. Bellon JA, Moreno-Peral P, Motrico E, Rodriguez-Morejon A, Fernandez A, Serrano-Blanco A, Zabaleta-del-Olmo E, Conejo-Ceron S. Effectiveness of psychological and/or educational interventions to prevent the onset of episodes of depression: a systematic review of systematic reviews and meta-analyses. Prev Med. 2015;76(Suppl):S22–32. doi: 10.1016/j.ypmed.2014.11.003.
    1. van Zoonen K, Buntrock C, Ebert DD, Smit F, Reynolds CF, 3rd, Beekman AT, Cuijpers P. Preventing the onset of major depressive disorder: a meta-analytic review of psychological interventions. Int J Epidemiol. 2014;43(2):318–29. doi: 10.1093/ije/dyt175.
    1. Conejo-Cerón S, Moreno-Peral P, Rodríguez-Morejón A, Motrico E, Navas-Campaña D, Rigabert A, Bellon JA. Effectiveness of psychological and/or educational interventions to prevent depression in primary care: a systematic review and meta-analysis. Ann Fam Med. 2017;15:262–71. doi: 10.1370/afm.2031.
    1. Mihalopoulos C, Chatterton ML. Economic evaluations of interventions designed to prevent mental disorders: a systematic review. Early Interv Psychiatry. 2015;9(2):85–92. doi: 10.1111/eip.12156.
    1. Marshall M. A precious jewel—the role of general practice in the English NHS. N Engl J Med. 2015;372(10):893–7. doi: 10.1056/NEJMp1411429.
    1. Jacka FN, Reavley NJ, Jorm AF, Toumbourou JW, Lewis AJ, Berk M. Prevention of common mental disorders: what can we learn from those who have gone before and where do we go next? Aust N Z J Psychiatry. 2013;47(10):920–9. doi: 10.1177/0004867413493523.
    1. Bellon JA, de Dios LJ, King M, Moreno-Kustner B, Nazareth I, Monton-Franco C, GildeGomez-Barragan MJ, Sanchez-Celaya M, Diaz-Barreiros MA, Vicens C, et al. Predicting the onset of major depression in primary care: international validation of a risk prediction algorithm from Spain. Psychol Med. 2011;41(10):2075–88. doi: 10.1017/S0033291711000468.
    1. King M, Walker C, Levy G, Bottomley C, Royston P, Weich S, Bellon-Saameno JA, Moreno B, Svab I, Rotar D, et al. Development and validation of an international risk prediction algorithm for episodes of major depression in general practice attendees: the PredictD study. Arch Gen Psychiatry. 2008;65(12):1368–76. doi: 10.1001/archpsyc.65.12.1368.
    1. Bellon JA, Conejo-Ceron S, Moreno-Peral P, King M, Nazareth I, Martin-Perez C, Fernandez-Alonso C, Rodriguez-Bayon A, Fernandez A, Aiarzaguena JM, et al. Intervention to prevent major depression in primary care: acluster randomized trial. Ann Intern Med. 2016;164:656–65. doi: 10.7326/M14-2653.
    1. Bellon JA, Conejo-Ceron S, Moreno-Peral P, King M, Nazareth I, Martin-Perez C, Fernandez-Alonso C, Ballesta-Rodriguez MI, Fernandez A, Aiarzaguena JM, et al. Preventing the onset of major depression based on the level and profile of risk of primary care attendees: protocol of a cluster randomised trial (the predictD-CCRT study) BMC Psychiatry. 2013;13:171. doi: 10.1186/1471-244X-13-171.
    1. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, Group C. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148(4):295–309. doi: 10.7326/0003-4819-148-4-200802190-00008.
    1. Salvador-Carulla L, Costa-Font J, Cabases J, McDaid D, Alonso J. Evaluating mental health care and policy in Spain. J Ment Health Policy Econ. 2010;13(2):73–86.
    1. Borkan J, Eaton CB, Novillo-Ortiz D, Rivero Corte P, Jadad AR. Renewing primary care: lessons learned from the Spanish health care system. Health Aff (Millwood) 2010;29(8):1432–41. doi: 10.1377/hlthaff.2010.0023.
    1. Excellence NIfHaC. Guide to the methods of technology appraisal 2013. London: NICE; 2013
    1. Vazquez-Barquero JL, Gaite L, Cuesta MJ, Carcia-Usieto E, Knapp M, Beecham J. Spanish version of the CSRI: a mental health cost evaluation interview. Archivos de Neurobiologia (Madrid) 1997;60:171–84.
    1. Kessler RC, Barber C, Beck A, Berglund P, Cleary PD, McKenas D, Pronk N, Simon G, Stang P, Ustun TB, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ) J Occup Environ Med. 2003;45(2):156–74. doi: 10.1097/01.jom.0000052967.43131.51.
    1. Herdman M, Badia X, Berra S. EuroQol-5D: a simple alternative for measuring health-related quality of life in primary care. AtenPrimaria. 2001;28:425–30.
    1. Parkin D, Devlin N. Is there a case for using visual analogue scale valuations in cost-utility analysis? Health Econ. 2006;15(7):653–64. doi: 10.1002/hec.1086.
    1. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2007.
    1. Rubin D. Multiple imputations for nonresponse in surveys. New York: Wiley; 1987.
    1. Briggs AH, O’Brien BJ, 2 The death of cost-minimization analysis? Health Econ. 2001;10:179–84. doi: 10.1002/hec.584.
    1. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry. 2005;187:106–8. doi: 10.1192/bjp.187.2.106.
    1. Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL. What is an efficient health technology in Spain? Gac Sanit. 2002;16:334–43. doi: 10.1016/S0213-9111(02)71933-X.
    1. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–7. doi: 10.1056/NEJMp1405158.
    1. Gomes M, Ng ES, Grieve R, Nixon R, Carpenter J, Thompson SG. Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials. Med Decis Making. 2012;32(2):350–61. doi: 10.1177/0272989X11418372.
    1. Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ. 2003;327(7424):1144–6. doi: 10.1136/bmj.327.7424.1144.
    1. Lee ML, Yano EM, Wang M, Simon BF, Rubenstein LV. What patient population does visit-based sampling in primary care settings represent? Med Care. 2002;40:761–70. doi: 10.1097/00005650-200209000-00006.
    1. Dowrick CF, Bellón JA, Gómez MJ. GP frequent attendance in Liverpool and Granada: the impact of depressive symptoms. Br J Gen Pract. 2000;50:361–5.
    1. Puffer S, Torgerson D, Watson J. Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals. BMJ. 2003;327:785–9. doi: 10.1136/bmj.327.7418.785.
    1. Hunter RM, Nazareth I, Morris S, King M. Modelling the cost-effectiveness of preventing major depression in general practice patients. Psychol Med. 2014;44(7):1381–90. doi: 10.1017/S0033291713002067.
    1. van den Berg M, Smit F, Vos T, van Baal PH. Cost-effectiveness of opportunistic screening and minimal contact psychotherapy to prevent depression in primary care patients. PLoS ONE. 2011;6(8):e22884. doi: 10.1371/journal.pone.0022884.

Source: PubMed

3
Se inscrever